Clik here to view.
Intensity Therapeutics begins human testing of intratumoral cancer drug
Intensity Therapeutics said today that the 1st patient was treated in a Phase I/II trial of its intratumorally-administered cancer therapy, INT230-6. The company’s plans to evaluate the safety of its...
View ArticleClik here to view.
Mallinckrodt faces probe over price hikes for injectable pain-killer
Sen. Claire McCaskill (D-Mo.) penned a letter to Mallinckrodt Pharmaceuticals (NYSE:MNK) last week, probing for details about the company’s pricing strategies for its injectable pain-killer, Ofirmev....
View ArticleClik here to view.
Novo Nordisk seeks to include cardiovascular data in Tresiba insulin label
Novo Nordisk (NYSE:NVO) said today that it submitted a supplemental application to the FDA, asking to include cardiovascular data on the label of its Tresiba insulin degludec. The Danish insulin-maker...
View ArticleClik here to view.
Medtronic launches opioid-induced respiratory depression study
Medtronic (NYSE:MDT) said today that it’s starting a large study on the effect of pulse oximetry and capnography in opioid-induced respiratory depression, using its Capnostream device. The...
View ArticleClik here to view.
Nanoparticles: An industry buzzword meets reality
Young startups backed by nanoparticle tech face a world hurdles before reaching the clinic. It’s been decades since the first innovations with nanotechnology – and experts are asking, “Where are all...
View ArticleClik here to view.
Bayer wins FDA nod for connected MS auto-injector
Bayer (ETR:BAYN) said yesterday that the FDA approved a supplemental biologics license application for the BetaConnect Navigator and myBetaApp – software for its electronic BetaConnect auto-injector....
View ArticleClik here to view.
Mallinckrodt mulls sale of generics biz
Mallinckrodt Pharmaceuticals (NYSE:MNK) is reportedly considering a sale of its generic drug unit in an effort to focus its portfolio on high-margin branded drugs, according to a report from Reuters....
View ArticleClik here to view.
Mylan board faces pressure from pension funds
Investors, including the New York City and State pension funds and the California State Teacher’s Retirement System, are urging shareholders to vote against Mylan (NSDQ:MYL) chairman Robert Coury and 5...
View ArticleClik here to view.
Report: Mylan may have overcharged US by $1.3B for EpiPen
Mylan (NSDQ:MYL) shares dipped slightly in mid-afternoon trading today after Sen. Chuck Grassley’s (R-Iowa) office released a Health and Human Services estimate claiming that taxpayers overpaid by as...
View ArticleClik here to view.
Vetter, Microdermics ink deal to develop novel microneedle drug delivery system
Prefilled drug delivery system developer Vetter and medical device maker Microdermics said yesterday that the companies are working to develop a novel microneedle drug delivery system. Microdermics has...
View ArticleClik here to view.
Philips, Illumina to launch precision medicine cancer program with Navican
Royal Philips (NYSE:PHG) and Intermountain Healthcare company Navican inked an agreement today to launch a precision health informatics solution aimed at improving outcomes for late stage cancer...
View ArticleClik here to view.
MannKind inks deal to bring inhaled insulin to Brazil
MannKind Corp. (NSDQ:MNKD) said today that inked a supply and distribution deal with Biomm for the commercialization of its inhaled insulin, Afrezza, in Brazil. According to the agreement, Biomm will...
View ArticleClik here to view.
BioCorRx partners with virtual reality center for naltrexone implant study
BioCorRx (OTC:BICX) said today that it partnered with the Virtual Reality Medical Center to conduct a study on the company’s long-lasting naltrexone implant. BioCorRx’s recovery program consists of a...
View ArticleClik here to view.
Critics allege misleading campaigns, poorly-cited data fueled opioid...
The state of Ohio filed a lawsuit against opioid-makers this week, alleging that the companies produced misleading marketing schemes to convince doctors and patients that opioids were not addictive....
View ArticleClik here to view.
Maryland becomes 1st state to pass generic drug price gouging law
Maryland is slated to become the 1st state to pass a law banning “price gouging” by generic pharmaceutical manufacturers. The bill was passed by the Maryland general assembly in April and last month...
View ArticleClik here to view.
Cingulate moves controlled-release ADHD drug to human testing
Cingulate Therapeutics said this week that it began a proof-of-concept trial for its controlled-release attention deficit/hyperactivity disorder drug. The 4-week clinical trial is being conducted by...
View ArticleClik here to view.
Novartis, IBM Watson collab to optimize care for patients with advanced...
Novartis (NYSE:NVS) said today that it inked a deal with IBM Watson Health to optimize care and improve outcomes for patients with advanced breast cancer. The 2 companies plan to develop a “cognitive...
View ArticleClik here to view.
AntriaBio seeks FDA nod for trial of once-weekly insulin
AntriaBio (OTC:ANTB) said today that it filed an investigational new drug application with the FDA for its once-weekly basal insulin. If the Louisville, Colo.-based company wins approval from the FDA,...
View ArticleClik here to view.
Insulet brings on new chief commercial exec | Personnel Moves – June 5, 2017
Insulet (NSDQ:PODD) last month named Bret Christensen as its chief commercial officer to lead the company’s sales, marketing, customer care, market access and advocacy. He most recently served as GM of...
View ArticleClik here to view.
Report finds Pfizer has hiked prices of nearly 100 drugs this year
As other major pharma players like Merck (NYSE:MRK) and Johnson & Johnson (NYSE:JNJ) vow to limit annual price hikes, a report by the Financial Times found that Pfizer (NYSE:PFE) has raised prices...
View Article